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Abstract
Background: The active form of vitamin D (1,25(OH)2D3) has been shown to inhibit development
of inflammatory bowel disease (IBD) in IL-10 KO mice. Here, the role of the vitamin D receptor
(VDR) and 1,25(OH)2D3 in acute experimental IBD was probed.
Results: VDR KO mice were extremely sensitive to dextran sodium sulfate (DSS) and there was
increased mortality of the VDR KO mice at doses of DSS that only caused a mild form of colitis in
wildtype (WT) mice. DSS colitis in the VDR KO mice was accompanied by high colonic expression
of TNF-α, IL-1 α, IL-1β, IL-12, IFN-γ, IL-10, MIP-1α and KC. DSS concentrations as low as 0.5%
were enough to induce bleeding, ulceration and weight loss in VDR KO mice. VDR KO mice failed
to recover following the removal of DSS, while WT mice showed signs of recovery within 5 days
of DSS removal. The early mortality of DSS treated VDR KO mice was likely due to perforation of
the bowel and resulting endotoxemia. VDR KO mice were hyper-responsive to exogenously
injected LPS and cultures of the peritoneal exudates of moribund DSS treated VDR KO mice were
positive for bacterial growth. 1,25(OH)2D3 in the diet or rectally decreased the severity and extent
of DSS-induced inflammation in WT mice.
Conclusion: The data point to a critical role for the VDR and 1,25(OH)2D3 in control of innate
immunity and the response of the colon to chemical injury.
Background
The two forms of inflammatory bowel disease (IBD):
Crohn's disease and ulcerative colitis are chronic diseases
characterized by aberrant responses to luminal bacteria in
genetically susceptible subjects [1]. Although IBD are
chronic diseases, the initiation of the inflammation and
reactivations of the disease are associated with engage-
ment of the innate immune response and progressive
induction of IL-12, IL-1β, and TNF-α in the intestine [2].
The vitamin D receptor (VDR) is a ligand inducible tran-
scription factor that has been shown to be an important
regulator of many experimental autoimmune diseases
including IBD [3]. A major source of vitamin D results
from its manufacture via a photolysis reaction in the skin.
Dietary intake of vitamin D is problematic since there are
few foods, which are naturally rich in vitamin D. There is
mounting evidence for a link between vitamin D availa-
bility either from sunshine or diet and the prevalence of
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IBD [3]. In addition, vitamin D deficiency is common in
patients with IBD [4]. Vitamin D is biologically inactive
and two hydroxylation reactions occurring in the liver and
kidney result in production of active vitamin D
(1,25(OH)2D3). 1,25(OH)2D3is the form of vitamin D
that binds to the VDR and inhibits experimental autoim-
munity.
Vitamin D deficiency and VDR deficiency have been
shown to exacerbate chronic IBD in IL-10 KO mice [5,6].
Furthermore, treatment of IL-10 KO mice with
1,25(OH)2D3 resulted in the suppression of IBD symp-
toms [5]. The effects of vitamin D and 1,25(OH)2D3 in
IBD have begun to be explored and include direct effects
of vitamin D on T cells and innate immune cells. Suppres-
sion of TNF-α is one mechanism underlying the efficacy
of 1,25(OH)2D3 in vivo [7]. In the gut it is likely that the
targets of vitamin D will include epithelial cells, innate as
well as acquired immune cells.
Macrophage are important vitamin D targets since they
are a potential source of the 1 alpha hydroxylase enzyme
(Cyp27B1) that converts the provitamin D hormone
25(OH)D3 to active VDR binding 1,25(OH)2D3 [8]. Mac-
rophage expression of Cyp27B1 has been shown to be
increased following TLR ligation in vitro [9]. Macrophage
and the TLR pathways are critical regulators of experimen-
tal IBD. The TLR-4, TLR-2 and MyD88 KO mice are
extremely susceptible to dextran sodium sulfate (DSS)
induced colitis [10]. Little is known on whether vitamin D
regulates these pathways to maintain gastrointestinal
homeostasis in vivo.
DSS initiates mucosal epithelial cell damage by disrupting
barrier function, leading to ulceration, and bleeding [11].
A relatively slow mucosal repair process occurs following
withdrawal of DSS in wildtype (WT) mice [11]. DSS
induced colitis results due to stimulation of the innate
immune response since T and B cell-deficient animals
such as SCID mice [12], and also SCID mice depleted of
NK cells develop DSS colitis [13]. The model is character-
ized by macrophage production of IL-1β, IL-6, and TNF-α
[13]. Macrophage induction at mucosal surfaces are early
triggers in an inflammatory cascade that leads to destruc-
tion of the intestinal wall.
The role of the VDR and 1,25(OH)2D3 in regulation of the
early innate immune response to DSS was probed in mice.
Expression of the VDR was found to be critical to control
the innate immune response in the gut. In addition, VDR
KO mice had a delayed recovery following DSS with-
drawal. 1,25(OH)2D3 treatments were protective and con-
trolled the early innate response in the colon. VDR KO
mice were extremely susceptible to the TLR-4 ligand LPS
and furthermore the early death of the VDR KO mice fol-
lowing DSS challenge was associated with bacterial recov-
ery from the peritoneal cavity.
Results
Acute DSS colitis is fatal in VDR KO mice
WT and VDR KO mice were induced to develop DSS coli-
tis. At 3.5% DSS the VDR KO mice began to die the 6th day
post-DSS administration and by 8 days there was 100%
mortality of VDR KO mice (Fig. 1A). Severe diarrhea,
bleeding and the loss of more than 25% of the BW pre-
ceded mortality of the VDR KO mice. The dosage of DSS
was reduced to 2.5% DSS. The mortality of VDR KO (n =
58) mice reached over 80% by day 12 post DSS (Fig. 1A)
when the mice lost 25% of their BW (Fig. 2B). At doses of
either 2.5% or 3.5% DSS the WT (n = 36) mice did not die
and lost only 10% of their BW while showing only mild
diarrhea and bleeding.
Delayed recovery of the VDR KO mice following removal 
of DSS
In this acute colitis model there is a recovery phase that
follows the cessation of DSS [14]. WT mice recovered
body weight (Fig. 1B) and the colon lengthened (Fig. 1C)
within 5 days of DSS removal as expected. The recovery
phase was delayed in surviving VDR KO mice when com-
pared to WT mice as evident by the ultimate inability of
VDR KO mice to completely regain BW even 30 days after
treatment was stopped (Fig. 1B). Conversely, by day 10
post DSS the WT colons had recovered completely (Fig.
1C) while the VDR KO colons were still significantly
shortened and not different than 5 days post DSS (Fig.
1C). Even at lower doses of DSS (1.5%) the recovery
period for VDR KO mice was 33 +/- 3.5 days while for WT
mice weight was completely regained by 12+/- 1.5 days.
VDR KO mice are sensitive to very low doses of DSS
Very low doses of (0.5%–2%) DSS that produce little to
no harm to the WT intestinal mucosa were tested in VDR
KO mice. In VDR KO mice, a dose of 0.5%–1% DSS
induced a loss of approximately 15%–18% of the initial
BW while this dose of DSS did not affect the BW of WT
mice (Fig 1D). A dose of 0.5% DSS in VDR KO mice
induced the same decrease in BW as 2.5% DSS in the WT
mice (Fig. 1D).
Hematological and histological alterations in DSS-treated 
VDR KO mice
Beginning with day 1 post-DSS administration, blood was
detected in the feces of VDR KO mice. Multiple bleeding
ulcerations of the intestinal mucosa occurred early and
with greater severity in VDR KO mice following DSS
administration (Fig. 3). The colon of the VDR KO mice
contained blood and scored significantly higher using the
colonic blood score than the WT mice (Fig. 2A). Conse-
quently, VDR KO mice became severely anemic; demon-BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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strated by low red blood cells and hematocrit
concentrations (data not shown). In addition, the VDR
KO mice had increased white blood cell counts, neu-
trophils and lymphocytes compared to WT mice at 5 d
post-DSS (Fig. 2B). Peritoneal exudate fluid was collected
and bacterial cultures were made from VDR KO mice that
were either treated or not with DSS. Moribund VDR KO
mice treated with DSS had positive bacterial cultures
(untreated mice were negative) that prove that bacteria
was translocating out of the gut and into systemic circula-
tion (data not shown). It is likely that VDR KO mice were
dying of severe bleeding and endotoxemia following per-
foration of the bowel induced by DSS.
At 3.5 % DSS the VDR KO colon showed a complete
destruction of the mucosal surface with most of the epi-
thelium lost and few intact crypts remaining (Fig. 3D). At
lower doses of DSS the mucosal damage was less although
there were isolated areas where the mucosal surface was
absent (Fig. 3F). Both the VDR KO and WT sections
showed signs of inflammation and thickening in the outer
colonic wall (Fig. 3); however the extent of the damage to
the VDR KO mouse was more extensive and failed to
resolve. Edema was evident in many of the VDR KO sec-
tions (Fig. 3F) and there were significant amounts of
blood in the colon after 10 days of DSS but only in the
VDR KO sections (Fig. 3H). Blinded scoring of the his-
topathology sections from VDR KO mice indicate that
VDR KO mice had significantly more inflammation,
injury and crypt damage than their WT counterparts at
both 5 and 10 days post 2.5% DSS administration (Fig. 4,
*P < 0.05).
Increased mortality of VDR KO mice following DSS administration Figure 1
Increased mortality of VDR KO mice following DSS administration. A) Survival curves in VDR KO and WT mice 
induced to develop DSS colitis. VDR KO mice died following 2.5% or 3.5% DSS treatment while all of the WT mice survived 
regardless of DSS concentrations. B) BW recovery over time post-DSS treatment. Mice were treated with 2.5% DSS for 5 
days. VDR KO mice failed to recover BW following cessation of DSS. C) Colon length at day 0 (control-CTRL), day 5 and day 
10 of DSS-exposure in WT and VDR KO mice. D) VDR KO mice were administered 0.5%–2% and WT mice received 1–2% 
DSS (n = 5/group). BW changes were monitored, and the values are expressed as the percentage of original BW. *Values from 
VDR KO mice were significantly different than corresponding values from WT mice. ** WT day 10 colon lengths were signifi-
cantly longer than WT day 5 colon lengths.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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Over-expression of many cytokines in the colon of VDR KO 
mice treated with DSS
Colonic extracts from VDR KO mice treated with DSS
showed high levels of TNFα, IL-12, IL-10, IL-1α and IL-1β
(Fig 5). The levels of these cytokines were significantly
higher in VDR KO mice compared to WT mice (Fig. 5). By
10 days post-DSS treatment WT mice had very little IL-10,
IL-1α, and IL-1β and no detectable levels of IL-12, and
TNF-α while the levels in the VDR KO colons remained
elevated even though the mice had been fed water for 5
days (Fig. 5).
Chemokines recruit neutrophils, macrophage and other
effector immune cells to the site of injury. While, the
colons of WT and VDR KO mice produced undetectable
levels of KC-1, and MIP-1 prior to DSS administration
(data not shown); KC-1 and MIP-1 were detectable 5 days
after the administration of DSS (Fig. 5) in the colon of
both the VDR KO and WT mice. MIP-1 was significantly
higher at 5 and 10 days post DSS treatment in VDR KO
mice compared to WT mice (Fig. 5). KC production was
increased to a similar level in colonic extracts from VDR
KO and WT mice 5 days after DSS treatment (Fig. 5) and
then decreased in both mouse types by day 10. However,
at day 10 VDR KO mice had significantly higher levels of
KC in the colon compared to WT mice (Fig. 5).
Lethal endotoxemia in VDR KO mice
The increased lethality of VDR KO mice following DSS-
administration may be a result of endotoxemia following
perforation of the large intestine. VDR KO mice (n = 11)
and WT (n = 10) mice were injected with the bacterial
outer wall component LPS and survival was assessed daily
for 7 days (Fig. 6). Shortly after intravenous administra-
tion of LPS VDR KO mice became extremely ill, experienc-
ing diarrhea, hunched posture, shaking and lethargy.
Similar results were seen when VDR KO mice were
injected ip using the same doses of LPS. Eighty percent of
VDR KO mice died during the first 4 days post-injection
and only 20% survived to day 7. In contrast, 70% of the
WT mice survived through day 7 after LPS injection (p <
0.001). PBS-injected VDR KO (n = 3) and WT (n = 3) mice
remained healthy throughout the 7-day study (data not
shown).
1,25 (OH)2D3 improves symptoms of DSS colitis in WT 
mice
Oral administration of 1,25(OH)2D3 (total dose of 1,400
ng/mouse) had no effect on the wasting associated with
DSS induced colitis in WT mice (data not shown). How-
ever, the 1,25(OH)2D3 feeding significantly up-regulated
IL-10 production in colonic homogenate at 14 days post-
DSS induction (Fig. 7A) and this was associated with
decreased total histopathological score (Fig. 7B). There
was no difference in other cytokines (IL-1, TNF-α or IL-
12) measured in the colonic homogenate between
1,25(OH)2D3-fed and control mice (data not shown). The
calcium level in the blood of 1,25(OH)2D3 fed mice and
controls were not different at the end of the experiment
(data not shown). 1,25(OH)2D3  (10 ng, 10 IU) was
administered intra-rectally so that delivery of the
1,25(OH)2D3  dose was to the site of inflammation
(colon). The 1,25(OH)2D3  treated (1,25D3) WT mice
shown in Fig. 7C and 7D received a total of 600 ng
1,25(OH)2D3. Rectal administration of 1,25(OH)2D3 did
not affect serum calcium values (data not shown) while
the 1,25(OH)2D3 treatment prevented body weight loses
(Fig. 7C) and resulted in microscopic improvement in his-
tology scores compared to controls (Fig. 7D). Rectal treat-
ment was more effective than feeding 1,25(OH)2D3 for
decreasing the severity of DSS colitis since the same result
occurred using only half the dose rectally.
VDR KO mice have blood in the colon and altered white  blood cell values compared to WT mice Figure 2
VDR KO mice have blood in the colon and altered 
white blood cell values compared to WT mice. A) 
Colonic blood score as a function of time post-DSS. Two 
WT and 2 VDR KO mice were sacrificed each day after 2.5% 
DSS administration and colonic blood score was assessed as 
described in the Materials and Methods. B) Hematological 
changes in WT and VDR KO mice following 2.5% DSS 
administration. Error bars represent ± SEM. * WT and VDR 
KO values were significantly different.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
Page 5 of 11
(page number not for citation purposes)
Colitis development following DSS administration Figure 3
Colitis development following DSS administration. Representative sections and histological assessment of colonic sam-
ples from A) WT and B) VDR KO mice receiving water; C) WT and D) VDR KO mice 5 days after receiving 3.5% DSS; E) 
WT and F) VDR KO mice 5 days after 2.5% DSS; G) WT and H) VDR KO mice 10 days after 2.5% DSS. Edema (asterisk), cel-
lular inflammation in all layers (arrows).BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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Discussion
Absence of the VDR results in mice that are extremely sus-
ceptible to chemical injury in the gut. DSS treated VDR
KO mice are anemic, have high white blood cell counts,
large amounts of blood in the colon, and many inflamma-
tory cytokines expressed at high levels. A breach in the
intestinal mucosa would lead to the entry of bacteria into
the blood stream followed by an excessive, uncontrolled,
systemic inflammation including, at the extreme, septic
shock. Masubuchi et. al have shown that endotoxin levels
detected in the portal blood of rats treated with DSS were
higher than those in control rats [15]. In humans, sys-
temic endotoxemia has been described in ulcerative colitis
[16,17] and Crohn's disease patients and shown to corre-
late positively with disease activity, pro-inflammatory
cytokine production and the extent of intestinal ulcera-
tion [18-23]. VDR deficient mice are extremely sensitive to
intravenous or intraperitoneal administration of LPS, sup-
porting the possibility that VDR KO mice with colitis die
due to endotoxemia. In addition, bacteria was cultured
from the peritoneal cavities of moribund VDR KO mice
following DSS treatment. All of the data support the hypo-
thesis that the early mortality of the VDR KO mice treated
with DSS is due to perforation of the gut and resulting
endotoxemia.
DSS induced colitis is a chemical that damages the colonic
epithelium [24] with subsequent recruitment and activa-
tion of inflammatory cells and upregulation of inflamma-
tory mediators [25]. During injury or inflammation,
intestinal epithelial cells are rapidly proliferating and this
process of mucosal repair and regeneration is critical for
gut homeostasis [26]. The VDR is highly expressed in
human [27] and mouse [28] colonic mucosa and intesti-
nal epithelial cells [29]. 1,25(OH)2D3 has been shown to
control normal villus and crypt development by regulat-
ing proliferation and differentiation of intestinal cells
[30]. Furthermore, 1,25(OH)2D3 is an important regula-
tor of cell growth and differentiation in many tissues
including the colon [31]. In DSS colitis most of the path-
ological changes are localized to the distal colon which is
a site of low proliferation of epithelial cells [31]. Others
have shown that the baseline proliferative state of colonic
eptithelial cells in the crypts of VDR KO mice are elevated
Histology scores in mice treated with DSS Figure 4
Histology scores in mice treated with DSS. Colonic injury score in WT and VDR KO mice that received 2.5%DSS at 5 or 
10 days post-administration. Scores were determined as described in Materials and Methods. * VDR KO values were signifi-
cantly different than WT mice at 5 days post-DSS. ** VDR KO values were significantly different than WT at 10 days post-DSS.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
Page 7 of 11
(page number not for citation purposes)
Cytokine and chemokine production after DSS-induced colitis Figure 5
Cytokine and chemokine production after DSS-induced colitis. TNF-α, IL-12, IFN-γ IL-1α, IL-1β, IL-10, MIP-1α, KC 
protein expression in colonic homogenates. * VDR KO values were significantly different than WT mice at 5 days or ** 10 days 
post-DSS.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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and showed increased expression of markers for cycling
cells (proliferating cell nuclear antigen and cyclin D1)
when compared to WTs [31]. Although increased prolifer-
ation in the colon of VDR KO mice might be seen as ben-
eficial, it has been shown that crypts with increased
numbers of epithelial cells in cell cycle are more suscepti-
ble to radiation-induced injury as determined by their ina-
bility to repopulate the crypt [32]. The effectiveness of
1,25(OH)2D3 in protecting the colon and the heightened
susceptibility of the VDR KO gut to DSS colitis is likely
due in part to the importance of vitamin D and VDR sign-
aling in control of epithelial growth and proliferation.
Once the mucosal barrier is breached, the submucosa is
exposed to a vast pool of luminal antigens, including
foods and bacteria, and the innate immune responses are
engaged to produce large amounts of cytokines. Analysis
of cytokine production by colonic homogenates revealed
significant elevation of TNF-α, IL-1α, IL-1β, IL-12p70,
IFN-γ and IL-10 in VDR KO mice treated with DSS when
compared with WT mice. Human and animal studies sup-
port the idea that TNF-α and IFN-γ are important patho-
logical mediators of IBD [33]. In humans with IBD
approximately two thirds of the patients responded to
anti-TNF-α treatments [34], and in mice the intestinal
inflammation was significantly attenuated by anti-IFN-γ
and/or anti-TNF-α monoclonal antibodies [35]. The pro-
duction of IFN-γ, TNF-α, IL-1α and IL-1β in the colonic
homogenates of VDR KO mice was substantially higher at
10 days post-DSS than in WT mice consistent with the
observed delay in recovery from inflammation in these
mice. The prolonged expression of inflammatory
cytokines corresponded with the increased susceptibility
and delayed recovery of the VDR KO mice.
During experimental colitis members of the α-chemokine
family are involved in the recruitment of immune cells
and the development of intestinal inflammation. Ajuebor
et. al have shown in experimental IBD that colonic KC
and MIP-1α expression led to leukocyte recruitment in the
gut [36]. Furthermore studies by Banks et. al showed that
the expression of MIP-1α correlated with the severity of
colonic inflammation in patients with IBD [37]. The
increased levels of KC and MIP-1α in the colons of VDR
KO suggest that in the absence of the VDR many more
inflammatory cells may be recruited to the site of injury
and then produce inflammatory cytokines that result in
severe and fatal form of colitis.
1,25(OH)2D3  treatments both in the food or locally
reduced colitis symptoms in WT mice. 1,25(OH)2D3
treated WT mice had increased IL-10 production that
might serve to inhibit other cytokine responses and lead
to a dampening of the cytokine storm in the colon. Fur-
thermore 1,25(OH)2D3 has the ability to directly induce
antimicrobial gene expression and activity of antimicro-
bial peptide CAMP and defensin β2 genes [38]. CAMP is
a potent antisepsis agent that blocks macrophage induc-
tion, enhances the survival of mice treated with lethal
doses of LPS [39] and accelerates epithelial wound heal-
ing [40]. The induction of CAMP and other antimicrobial
genes suggested that 1,25(OH)2D3 might be protective
against sepsis after injury and might accelerate epithelial
wound healing [38].
Conclusion
A model develops where the 1,25(OH)2D3 that is either
produced or administered locally in the colon increases
epithelial cell resistance to injury and suppresses innate
immune responses to luminal antigens through VDR sig-
naling. In the absence of the VDR inflammation in the gut
is amplified, colonic epithelial cell proliferation is unreg-
ulated and the host fails to adequately maintain gastroin-
testinal integrity following chemical insult. The data
identify vitamin D as a key regulator of gastrointestinal
homeostasis and an important player in regulation of the
innate immune response.
Methods
Mice
Weight (20–25 g) and sex matched 10–12 week old
C57BL/6 WT and VDR KO (C57BL/6, gift from M. Demay,
Harvard University, Cambridge, MA) were bred for use at
the Pennsylvania State University (University Park, PA).
All procedures were reviewed and approved by the Penn-
sylvania State University Institutional Animal Care and
Use Committee.
LPS induced endotoxemia Figure 6
LPS induced endotoxemia. The survival of VDR KO (n = 
11) and WT (n = 10) mice injected i.v. with 10 mg/kg LPS.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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Induction of colitis
Mice were administered 0.5%–3.5% DSS (MW = 40 kDa;
ICN Biomedicals, Aurora, OH) dissolved in filter-purified
and sterilized water ad libitum for 5 days, after which the
mice were resumed on water for the remainder of the
experiment. Animals were weighed daily and monitored
clinically for rectal bleeding, diarrhea, and general signs of
morbidity. Moribund mice or mice that had lost more
than 25% of their body weight were sacrificed and listed
as dead following induction of DSS colitis.
Colitis symptoms
The gross colonic blood scoring system previously
described by Siegmund et al[41] was used. The colonic
bleeding score was as follows: 0- no visible blood in the
entire colon, 1-blood detected in less than 1/3 of the
colon, 2- blood detected in less than 2/3 of the colon, 3-
blood visible throughout the entire colon. The entire
colon from cecum to anus was removed and the length
was measured and reported as colonic length as described
[11].
The distal colon were removed from the mice, fixed in
10% formalin and sent to the Pennslyvania State Univer-
sity Animal Diagnostic Laboratories (University Park, PA)
for H&E staining. Histological analysis was performed
blinded by 2 independent investigators on a scale from 0
to 40 as follows: severity of inflammation (0–3: none,
slight, moderate, severe), extent of injury (0–3: none,
mucosal, mucosal and submucosal, transmural), and
crypt damage (0–4: none, basal 1/3 damaged, basal 2/3
damaged, only surface epithelium intact, entire crypt and
epithelium lost). Each score was then multiplied by a fac-
tor equivalent with the percentage of tissue involvement
(× 1: 0–25%, × 2: 26–50%, × 3: 51–75%, × 4: 76–
100%)[42].
Peripheral blood analysis
Blood was collected by cardiac puncture in tubes coated
with EDTA (Becton Dickinson Vacutainer System, NJ) and
analyzed using an ADVIA 120 Hematology System (Bayer
Diagnostic, NY). For some experiments 100–200 μl of
blood was collected by retroorbital sinus bleeding using
heparinized microcapillary pipettes.
1,25(OH)2D3 ameliorates DSS colitis Figure 7
1,25(OH)2D3 ameliorates DSS colitis. A) IL-10 production from the colonic homogenates of control (CTRL) or 
1,25(OH)2D3 (1,25D3) fed mice. B) Total histological score was determined for control and 1,25D3 fed mice. C) Percent 
weight change of CTRL (n = 6) or 1,25D3 (n = 10) treated WT mice when the treatment was given rectally every other day. 
D) Colonic injury score in rectally treated CTRL and 1,25D3 mice at 10 days post-DSS. *CTRL and 1,25D3 values were signif-
icantly different at the corresponding time points.BMC Immunology 2007, 8:5 http://www.biomedcentral.com/1471-2172/8/5
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Colonic homogenate
The distal colon was weighed and the same amount of tis-
sue was cut open and washed in 1XPBS containing peni-
cillin (100 U/ml) and streptomycin (100 μg/ml). Tissue
was then homogenized in 1 ml PBS using a razor blade.
The homogenized colon tissue was centrifuged at 10,000
g at 4°C for 10 min. Cytokine concentrations were deter-
mined in the supernatant.
Cytokine and chemokine ELISA
Serum and supernatants were assayed for mouse TNF-α,
IL-12p70, IFN-γ, IL-1α, IL-1β, IL-10 production using Ab
pairs and standards provided in the BD Pharmingen kits
ELISA (San Diego, CA) according to the manufacturer's
instructions. For KC and MIP-1α the ELISA kits were from
R&D Systems. (Minneapolis, MN). The limits of detection
were 31 pg/ml TNF-α, 125 pg/ml IL-12 p70,125 pg/ml
IFN-γ, 31 pg/ml IL-1α, 31 pg/ml IL-1β, 31 pg/ml IL-10, 16
pg/ml KC and 31 pg/ml MIP-1α.
Endotoxic shock
C57BL/6 mice were injected iv or ip with LPS from
Escherichia coli 0111:B4 (Sigma, St Louis, MO) at a dose of
10 mg/kg body weight. Mice were monitored 3–4 times
daily during endotoxic shock, and moribund animals
were sacrificed.
1,25(OH)2D3 treatment
Mice received 50 ng/daily of 1,25(OH)2D3 in the diet as
described [5] elsewhere 1 week prior and throughout DSS
administration. For local treatment, 50 ng of
1,25(OH)2D3 was dissolved in 20 uL corn oil and admin-
istered rectally 1 day prior to DSS administration and
every other day thereafter for the duration of the experi-
ment. Control mice received the corresponding amount
of ethanol diluted in corn oil.
Statistical analysis
Statistical analysis was performed using the paired Stu-
dent's t test and ANOVAs (StatView; SAS Institute, Cary,
NC). P values < 0.05 were considered significant. Error
bars represent +/- SEM. The log-rank test was used to com-
pare Kaplan-Meier survival curves.
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